Grifols (GIKLY) Accounts Payables (2009 - 2025)
Grifols (GIKLY) posted Accounts Payables of $1.3 billion for Q4 2025, up 8.45% quarter-over-quarter from $1.2 billion in Q4 2024, and up 8.45% year-on-year from $1.2 billion in Q4 2024.
Grifols (GIKLY) Accounts Payables (2009 - 2025) Analysis & Trends
Grifols (GIKLY) has reported Accounts Payables for 16 consecutive years, with $1.3 billion the latest figure, recorded in Q4 2025.
- Accounts Payables for Q4 2025 came in at $1.3 billion, up 8.45% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.3 billion (up 8.45% YoY), and the FY2025 annual result was $1.3 billion, up 8.45% from the prior year.
- Accounts Payables was $1.3 billion for Q4 2025 at Grifols, up from $1.2 billion in the prior quarter.
- Over five years, Accounts Payables peaked at $1.3 billion in Q4 2025 and troughed at $719.5 million in Q4 2021.
- Average Accounts Payables over 5 years is $982.1 million, with a median of $885.4 million recorded in 2023.
- Year-over-year, Accounts Payables increased 0.31% in 2021 and soared 35.53% in 2024.
- Over 5 years, Accounts Payables stood at $719.5 million in 2021, then rose by 11.73% to $803.9 million in 2022, then increased by 10.14% to $885.4 million in 2023, then surged by 35.53% to $1.2 billion in 2024, then grew by 8.45% to $1.3 billion in 2025.
- Per Business Quant data, the three most recent Accounts Payables figures were $1.3 billion in Q4 2025, $1.2 billion in Q4 2024, and $885.4 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 5.03 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 10.46 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 33.77 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -22.51 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 3.86 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 2.94 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 645.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 4.51 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Grifols | - | - | - | 1.30 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.30 Bn |
| Dec 31, 2024 | 1.20 Bn |
| Dec 31, 2023 | 885.45 Mn |
| Dec 31, 2022 | 803.92 Mn |
| Dec 31, 2021 | 719.55 Mn |
| Dec 31, 2020 | 717.30 Mn |
| Dec 31, 2019 | 644.08 Mn |
| Dec 31, 2018 | 641.33 Mn |
| Jun 30, 2018 | 509.83 Mn |
| Dec 31, 2017 | 498.17 Mn |
| Jun 30, 2017 | 434.13 Mn |
| Dec 31, 2016 | 660.71 Mn |
| Sep 30, 2016 | 436.40 Mn |
| Jun 30, 2016 | 452.56 Mn |
| Dec 31, 2015 | 449.39 Mn |
| Sep 30, 2015 | 391.32 Mn |
| Jun 30, 2015 | 406,464.33 |
| Mar 31, 2015 | 430.85 Mn |
| Dec 31, 2014 | 549.47 Mn |
| Sep 30, 2014 | 521.73 Mn |